Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the therapeutics associated with the Hepatitis C disease. The information for particular drug in development process is represented in the form of tables and detailed analysis including the available Pharmacodynamics and Pharmacokinetics results.
This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the drug development process. Report also helps drug development organisation to keep track record the ongoing drug profiles being developed by their key competitor in the industry.
Following parameters for each drug profile in development phase are covered in “Hepatitis C Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Active Indication
- Phase of Development
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- Patent Information
- Molecular Formula
- Pharmodynamics
- Pharmacokinetics
- Brand Names
- Development Agreements
- ATC Codes
1.1 Overview
1.2 Drug profile
2. DEVELOPMENT PHASE: PRECLINICAL
2.1 Overview
2.2 Drug profile
3. DEVELOPMENT PHASE: PHASE-I
3.1 Overview
3.2 Drug profile
4. DEVELOPMENT PHASE: PHASE-I/II
4.1 Overview
4.2 Drug profile
5. DEVELOPMENT PHASE: PHASE-II
5.1 Overview
5.2 Drug profile
6. DEVELOPMENT PHASE: PHASE-II/III
6.1 Overview
6.2 Drug profile
7. DEVELOPMENT PHASE: PHASE-III
7.1 Overview
7.2 Drug profile
8. DEVELOPMENT PHASE: PREREGISTRATION
8.1 Overview
8.2 Drug profile
Anadys Pharmaceuticals (a subsidiary of Roche) is developing ANA 773, an orally administered, small molecule prodrug of a toll-like receptor 7 (TLR7) agonist, for thetreatment of chronic hepatitis C infections. A mechanism involving agonistic interaction with TLR7 is believed to stimulate the immune system against certain types of cancer and infections. ANA 773 has undergone phase I trials for solid tumours and hepatitis C in the US and the Netherlands, respectively. In 2009, Anadys suspended further development of ANA 773 in order to focus its resources on ANA 598, but reversed this in November 2010. ANA 773 remains on the Roche pipeline at phase I for hepatitis C viral infections. No further development is planned for cancer and development for this indication is thus presumed discontinued.
Hepatitis C: Anadys Pharmaceuticals initiated recruitment in the Netherlands into aphase IIa trial of ANA 773 in combination with ribavirin in patients with hepatitis Cinfections in May 2011 (ANA773-602; EudraCT2011-000728-14). The trial was going toenrol 75 patients in Europe. However, Anadys was acquired by Roche in late 2011, andthe trial was subsequently discontinued prematurely in February 2012. Roche had the compound listed as phase I on its pipeline.
Anadys completed a phase I trial of ANA 773 in patients with hepatitis C in the Netherlands in August 2009 (NCT01211626). In Part A of the trial, 40 healthy volunteerswere receiving single and multiple doses of ANA 773, and successive cohorts were receiving ascending doses. The primary endpoints were safety and tolerability. In Part B, patients with hepatitis C in the first cohort were to be given NA 773 800mg everyother day for 28 days. Viral load and tolerability data from the 800mg cohort were to be used to determine the dose levels for subsequent cohorts. Primary objectives were safety, tolerability and reduction in viral load. Dosing in Part A began in July 2008; dosing in Part B started in October 2008. In April 2009, Anadys announced that patientdosing in the phase I trial of ANA 773 in HCV had been completed through to 1600mg dosed every other day (QOD) also submitted an amendment to the study to test ANA 773 at 2000mg QOD. Preliminary data from the final cohort of patients with hepatitis Creceiving ANA 773 2000mg every other day for 10 days were presented in August 2009.
